P2X7 Receptor Deficiency Ameliorates STZ-induced Cardiac Damage and Remodeling Through PKCβ and ERK

Area of Science:

• Cardiovascular Research
• Diabetology
• Molecular Pharmacology

Background:

• Diabetic cardiomyopathy (DCM) is a significant complication of diabetes mellitus, leading to cardiac dysfunction and heart failure.
• The specific role of the P2X7 receptor (P2X7R) in the development of DCM remains largely unknown.

Purpose of the Study:

• To investigate the involvement of P2X7R in the pathogenesis of diabetic cardiomyopathy.
• To explore P2X7R as a potential therapeutic target for DCM.

Main Methods:

• Utilized a C57BL/6 mouse model of diabetes induced by streptozotocin (STZ).
• Administered the P2X7R inhibitor A438079 intraperitoneally and assessed cardiac function and remodeling.
• Conducted in vitro experiments using H9c2 cells and primary rat cardiomyocytes exposed to high glucose (HG).
• Examined the activation of downstream signaling pathways, including protein kinase C-β (PKCβ) and extracellular regulated protein kinases (ERK).

Main Results:

• Treatment with A438079 or genetic deficiency of P2X7R attenuated cardiac dysfunction and remodeling in diabetic mice.
• A438079 reduced high glucose-induced cell damage in cardiomyocytes in vitro.
• High glucose/STZ-induced P2X7R activation was found to mediate downstream activation of PKCβ and ERK.

Conclusions:

• P2X7 receptor signaling is implicated in the pathogenesis of STZ-induced diabetic cardiac damage and remodeling.
• The PKCβ/ERK signaling axis is a key downstream pathway mediating P2X7R's role in DCM.
• P2X7R inhibition presents a promising therapeutic strategy for managing diabetic cardiomyopathy.